Bioline Pulled Drug Trial, Stock Tumbled 50% Wednesday

Anti-psychotic drug under development proved no better than the standard schizophrenia medication.

Shares of Bioline tumbled 50% on Wednesday after the Israeli biomed company said it is halting Phase Israeli clinical trials of an anti-psychotic drug.